Demonstrates effective synthesis of GDC-6036 in a controlled manner, suggesting practical applications for KRAS G12C inhibition.
A chromatography-free asymmetric synthesis of GDC-6036 ( 1 ) was achieved via a highly atroposelective Negishi coupling of aminopyridine 5 and quinazoline 6b catalyzed by 0.5 mol % [Pd(cin)Cl] 2 and 1 mol % ( R, R )-Chiraphite to afford the key intermediate ( R a )- 3 . An alkoxylation of ( R a )- 3 with ( S )- N -methylprolinol ( 4 ) and a global deprotection generates the penultimate heterobiaryl intermediate 2 . A controlled acrylamide installation by stepwise acylation/sulfone elimination and final adipate salt formation and crystallization delivered high-purity GDC-6036 ( 1 ).
No takes yet. Share an insight, caveat, or question.
Xu et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: